He who saves one human life saves the world entire
Cancer takes the first place in the structure of morbidity and mortality from malignant neoplasms. It indicates the problem of patients and doctors’ unsatisfied needs in the treatment of this disease. Some types of cancer, such as melanoma, bladder or renal cell carcinoma, demonstrated a long-term response to immunotherapy, however, many more types of tumors respond poorly to cancer immunotherapy.  Because cancer is immunologically "cold", it is weakly infiltrated with T cells and causes a weak immune response. The causes of immune silence in cancer are not fully defined and this knowledge gap threatens the life and health of hundreds and thousands of patients.

The direction of the development of immunotherapy
Cancer treatment is in an “Immune Revolution”. For this created a different class of molecules. These molecules are divided into two main groups:
- those that target molecules whose action prevents the immune system from eradicating the tumor. The targeted molecules are involved in inhibitory pathways and immunotherapy drugs work by blocking these molecules (known as immune checkpoint inhibitors, ICI);
- those that target molecules whose action helps the immune system eradicate the tumor. The targeted molecules are involved in co-stimulatory pathways and immunotherapy drugs work by being agonists of these molecules.
It means that some molecules must block the activity of the protein (antagonists), while the others must enhance the activity of proteins (agonists).
All this predetermined the development of a new class of molecules with the properties of mixed agonists / antagonists. These are the new molecules Mercureid.

Multitarget immunotherapy of a new generation
Further studies of new therapeutic agents, mixed agonists / antagonists of nanomolecules Mercureid in multitarget immunotherapy targeted at reprogramming the activity of 10 receptor proteins, are crucial for the development of the most effective cancer treatment strategies. The biopharmaceutical company «Mercureid R&D» offers you information on the most important innovative research in cancer immunotherapy. We have developed new molecules for immunotherapy new generation.

We have created molecules Multitarget impact (on 10 proteins that are responsible for both the Immune checkpoint control processes and the activation processes of lymphocyte cytotoxicity)

 

The stereochemical properties of the MSC-428 molecules make it possible to act on several target proteins that are crucial for the antitumor response of the organism:

1. Changing the conformation of receptor proteins PD-1 is impeded by their association with ligands PD-L1.
2. Increases the expression of CD25 on the surface of T cells, which increases the cytotoxic potential of T killers.
3. Inhibits the activity of CD19, which interfere with the cytotoxic activity of CD8 and promote the anergy of cytotoxic cells in the tumor. CD19+ B lymphocytes cause in immune suppression and tumor evasion via PD-L1.
4. Molecule "MSC-428" inhibit the kinase ZAP-70, reduces the overexpression of CD38, which increases the effectiveness of the antitumor response of the body. Involves lymphocytes to the site of tumor localization. Allows to overcome the resistance to PD-1 / PD-L1/

Thus, «MSC-428» targeted for 4 target proteins, such as: PD-1 / PD-L1, CD19, CD25, CD38.
It should be noted that their activity recovery is largely predetermined by the normalization of other surface antigens of lymphocytes, such as: CD3, CD4, CD8, CD16, CD45, CD95, phagocyte system, immunoglobulin class A, M, G.
We used a fundamentally new approach that provides new opportunities for cancer therapy and prevention.

Know how
The possibilities of new Mercureid molecules provide new therapeutic strategies adapted to the evolution of the individual patient's cancer.
The era of Precision Oncology allows us to create molecules for a particular patient, in accordance with its genetic, phenotypic, and immune features.